Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q4 2017 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$4.03M$4.03Mderivedno prior Q4 2016 on file Net Income-$2.44M-$2.44MderivedN/M vs Q4 2016 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$1,945,000N/M Operating Incomederived-$2,914,000N/M Operating Cash Flowderived-$2,695,000N/M Free Cash Flowderived-$2,894,000N/M Margins · derivedGross margin48.3%
Operating margin-72.3%
Net margin-60.5%
ended Mar 31, 2017 · filed Jun 28, 2017 · 89 d after period end